Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 5Uterine Cervical Neoplasms 2Oropharyngeal Neoplasms 2Hodgkin Disease 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Plasma Cell 1Glioma 1Disease 1Carcinoma, Squamous Cell 1

Interventions

fludarabine 2Cyclophosphamide 2Carboplatin 2pembrolizumab 1fludarabine phosphate 1decitabine and cedazuridine drug combination 1Radiotherapy, Intensity-Modulated 1Platinum 1Pemetrexed 1Nivolumab 1Ipilimumab 1Fluorodeoxyglucose F18 1Cisplatin 1Cerebral Decortication 1Blood Component Removal 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × Fluorodeoxyglucose F18 × 30 days × Clear all
NCT06503146 2026-05-19

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
320 enrolled
CNSEndocrineGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡